EUCTR2011-000917-38-DE进行中（未招募）不适用
A first–in-human study to evaluate safety and tolerability of repeated topical administrations of BPR277 ointment in healthy volunteers, and safety, tolerability, and preliminary efficacy of multiple topical administrations of BPR277 in patients with atopic dermatitis and Netherton syndrome
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 85
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects eligible for inclusion in this study have to fulfill all of the following criteria. Other protocol-defined inclusion criteria apply in addition to those listed hereafter:
- •1.Written informed consent must be obtained before any assessment is performed.
- •2.Healthy male and female subjects of non childbearing potential, 18 to 65 years of age inclusive and in good health
- •3.Subjects must weigh at least 50kg to participate in the study, and must have a body mass index (BMI) within the range of 18-35kg/m2.
- •4.Study subjects must be able to communicate well with the investigator, to understand and comply with the requirements of the study.
- •1.Written informed consent must be obtained before any assessment is performed.
- •2.Male and female subjects, 18 to 65 years of age inclusive and having passed screening examinations
- •3.Presence of atopic dermatitis confirmed by Itchy skin condition in the past 12 months (must have)
- •Plus three or more of the following:
- •History of involvement of the skin creases
- •Personal history of asthma or hay fever
- •History of generally dry skin in the past year
- •Onset before age of 2 years
- •Visible flexural dermatitis
- •4.Diagnosis of at least moderate atopic dermatitis by the IGA of the to-be-treated area at screening; and a 250 cm2 to-be-treated area of skin containing at least ~50% AD affected skin. The 250 cm2 treatment area is to be ideally situated on the forearm including the antecubital fossa with a total lesional sign score (TLSS) of at least 10 at screening. Alternative locations for the treatment area are detailed in the protocol. Areas that
- •must not be chosen are: hands and feet, head and neck, back, armpits and the groin.
- •5.A total lesional sign score (TLSS) at baseline of 2-4 within the study treatment area.
- •6.Subjects must weigh at least 50 kg to participate in the study, and must have a body mass index (BMI) within the range of 18-42 kg/m2.
- •7.Study subjects must be able to communicate well with the investigator, to understand and comply with the requirements of the study
- •Part 3 Cohort A, AA and AB (patients with Netherton Syndrome):
- •Patients with Netherton syndrome, male and female subjects, 18 to 65 years of age inclusive and having passed screening examinations
- •Confirmed diagnosis of Netherton syndrome (SPINK5 mutation or LEKTI deficiency in the skin).
- •Minimum total lesional sign score NS (TLSS-NS) of 5-9 for two selected target areas at baseline. The TLSS-NS values need to be similar between the two areas at baseline.
- •Other protocol-defined inclusion/exclusion criteria may apply. Refer to protocol for details.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 85
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects fulfilling any of the following criteria are not eligible for inclusion in this study. Other protocol-defined exclusion criteria apply in addition to those listed hereafter:
- •1.Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer.
- •2.History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes or history of serious allergic reaction.
- •3.A history of clinically significant ECG abnormalities, or ECG abnormalities at Screening or Baseline.
- •4.History of malignancy of any organ system, treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
- •5.Use of any prescription drugs, herbal supplements, within four (4) weeks prior to initial dosing, and/or over-the-counter (OTC) medication, dietary supplements (vitamins included) within two (2) weeks prior to initial dosing.
- •6.Total WBC count which falls outside the range of 4500–11,000/µl, or platelets <100,000/µl, or hemoglobin levels below 12.0 g/dl at screening.
- •7.Donation or loss of 400 ml or more of blood within eight (8) weeks prior to initial dosing, or longer if required by local regulation.
- •8.Recent and/or recurrent history of autonomic dysfunction
- •9.Liver disease or liver injury as indicated by abnormal liver function tests
- •10.History or presence of impaired renal function
- •11.Evidence of urinary obstruction or difficulty in voiding at screening.
- •12.History of hypertrophic scarring.
- •13.History of immunodeficiency diseases.
- •1.Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer.
- •2.History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes or history of serious allergic reaction.
- •3.History of abnormal skin reactivity to UV light. Unusual exposure to UV light in the previous 3 weeks to study start (screening), including tanning and sun beds.
- •4.Pregnant or nursing (lactating) women.
- •5.Women of child-bearing potential must use highly effective contraception (as further defined in study protocol) during the study and the duration of the study.
- •6.Use of topical prescription treatment for eczema (topical corticosteroids, calcineurin inhibitors, antibiotics, etc...) on the selected study treatment area within 1 week prior to initial dosing of topical corticosteroids (TCS).
- •7.Recent previous treatment with phototherapy, biological therapy, immunosuppressive agents such as cyclosporine, mycophenolate, pimecrolimus or tacrolimus. A washout period will be required for such patients to be eligible to participate in the trial.
- •8.Donation or loss of 400 ml or more of blood within eight (8) weeks prior to initial dosing, or longer if required by local regulation.
- •9.History of malignancy of any organ system, treated or untreated, within the past 5 years.
- •10.History of clinically significant ECG abnormalities or Screening/Baseline ECG abnormalities
- •11.Inability or unwillingness to undergo multiple venipunctures
- •12.History of hypertrophic scarring.
- •Part 3 Cohorts A, AA & AB (patients with Netherton Syndrome):
- •History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes or history of serious allergic reaction.
- •History of abnormal skin reactivity to UV light. Unusual exposure to UV light in the previous 3 weeks to study start (
研究者
相似试验
进行中（未招募）
不适用
CBPR277X2101EUCTR2011-000917-38-NLovartis Pharma Services AG85
已完成
2 期
A first-in-human study to evaluate safety and tolerability of repeated topical administrations of BPR277 ointment in healthy volunteers, and safety, tolerability, and preliminary efficacy of multiple topical administrations of BPR277 in patients with atopic dermatitis and Netherton syndrome (CBPR277X2101)Netherton syndrome10040790NL-OMON40034ovartis Pharma BV5
已完成
不适用
A first-in-human study to evaluate the safety and performance of placebo excipient-coated high-density microarray patches applied by an integrated application device.VaccinationsPublic Health - Other public healthACTRN12620000179932Vaxxas Pty Ltd43
进行中（未招募）
1 期
Study to evaluate QR-421a in subjects with retinitis pigmentosa (RP) due to mutations in exon 13 of the USH2A GeneEUCTR2018-002433-38-FRProQR Therapeutics18
已完成
1 期
A first-in-human study to evaluate the safety tolerability and performance of A/California/7/2009 (H1N1)- like vaccine coated Nanopatches in comparison to placebo coated Nanopatches and intramuscular injection of A/California/7/2009 (H1N1)-like vaccine.. Nanopatches will be delivered to skin using the Vaxxas Clinical Applicator Disposable Device (CAPD).Prophylaxis for H1N1 infectionInfection - Other infectious diseasesACTRN12616000880448Vaxxas Pty Ltd60